Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Echinomycin SCHEMBL18506201 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL13464701 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL29529894 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL63091 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL30725384 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL18477111 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL13928604 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL20323949 | 0.96 | RIPK1 (0.31) | RIPK1 | |
| SCHEMBL12556535 | 0.95 | RIPK1 (0.31) | RIPK1 | |
| SCHEMBL29378829 | 0.95 | RIPK1 (0.32) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106877-A1 | INHALED HYPOXIA AND SMALL MOLECULE FORMS OF HYPOXIA AS NOVEL ANTICANCER AGENTS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2025-05-22 | — | — | WO | claimed |
| CN-119552794-B | Streptomyces glacialis with sbhR gene deleted and preparation method and application thereof | 中国农业科学院植物保护研究所 | 2025-05-16 | — | — | CN | claimed |
| CN-119552794-A | Streptomyces glacialis with sbhR gene deleted and preparation method and application thereof | 中国农业科学院植物保护研究所 | 2025-03-04 | — | — | CN | claimed |
| EP-3868409-B1 | THIOPHENOL-MALEIMIDE AND BROM-MALEIMIDE DERIVATIVES AS LINKER FOR ANTIBODY-DRUG CONJUGATES (ADC) FOR TREATING TUMORS | REMEGEN CO LTD (CN) | 2024-07-17 | — | — | EP | claimed |
| US-11964019-B2 | Cochleates made with soy phosphatidylserine | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-04-23 | — | — | US | claimed |
| US-20260116986-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | IMMUNEDGE INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025231217-A1 | COMPOSITIONS AND METHODS OF OLIGONUCLEOTIDE HITCHHIKING FOR ENCAPSULATION OF DRUGS IN LIPID NANOPARTICLES | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-11-06 | — | — | WO | disclosed |
| US-12409227-B2 | Cochleates made with soy phosphatidylserine | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-09-09 | — | — | US | disclosed |
| WO-2025106877-A1 | INHALED HYPOXIA AND SMALL MOLECULE FORMS OF HYPOXIA AS NOVEL ANTICANCER AGENTS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250146018-A1 | COMPOSITIONS AND METHODS FOR IMPEDING TRANSCRIPTION OF EXPANDED MICROSATELLITE REPEATS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-04-24 | — | — | US | disclosed |
| US-12180499-B2 | Compositions and methods for impeding transcription of expanded microsatellite repeats | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240316204-A1 | COCHLEATES MADE WITH SOY PHOSPHATIDYLSERINE | MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. | 2024-09-26 | — | — | US | disclosed |
| US-11964019-B2 | Cochleates made with soy phosphatidylserine | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-04-23 | — | — | US | disclosed |
| CN-115043892-B | Glycosyl polyether compounds targeting actin | 武汉合生科技有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230282311-A1 | METHOD AND SYSTEM TO IDENTIFY NATURAL PRODUCTS FROM MASS SPECTROMETRY AND GENOMICS DATA | UNITED STATES DEPARTMENT OF ENERGY | 2023-09-07 | — | — | US | disclosed |
| EP-4110405-A1 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | MCSAF INSIDE ONOCOLOGY (FR) | 2023-01-04 | — | — | EP | disclosed |
| EP-3972652-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | Mc SAF (FR) | 2022-03-30 | — | — | EP | disclosed |
| EP-3373993-B1 | SI-HPMC-ENCAPSULATED INSULIN-PRODUCING CELLS FOR THE TREATMENT OF TYPE 1 DIABETES | ECOLE NAT VETERINAIRE (FR) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, MPL, PRLHR | RIPK1 4047/4885 |
| US-20260116986-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, STAT5A, JAK2 | RIPK1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.